Company

Our mission is

to contribute to well-being of humanity by treating chronic immune diseases through peptide drugs we discover and develop.

Thank you for visiting our website.

KINE SCIENCES is a company that develops ultra-small peptide innovative medicines based on functional immunomics.

We discovered the function of a novel cytokine ERDR1 for the first time in the world and since we have been developing drug candidates of ultra-small peptide with private and public funding including the one from Korea Drug Development Fund for consecutive four years.

The diseases we aim to treat are chronic immune diseases such as rheumatoid arthritis, inflammatory bowel diseases, atopic dermatitis, psoriasis, cancer, Alzheimer’s disease, and many rare immune diseases.

Though we live in an era when we see more research on life sciences and more drugs on the market than any other era of human history, we humans have yet to find cures for these chronic immune diseases by seeing occurrence of resistance or relapse which make lifelong treatment of expensive medicines inevitable for patients.

These diseases put a great burden not only on patients themselves but their families and the society as a whole.

KINE SCIENCES is committed to treating chronic immune diseases, making lives of patients and their families better, and ultimately improving well-being of humanity by developing safer, more economical and more convenient medicines of ultra small peptides.

Please give us encouragement and support for our daunting journey.

Founder

  • Dae Ho Cho Ph.D

  • Ph.D, Chicago Medical School; B.S., SUNY

    Professor of Convergence Research Institute, Korea University

    Head of Nano Bio material Research Center, Korea University

    Professor of Department of Life Sciences, Sookmyung Women's University

  • Sa Ik Bang M.D, Ph.D

  • B.S., M.S., & Ph.D, Seoul National University, College of Medicine

    Professor of Medical School, Sungkyunkwan University

    Head of External Cooperation Office, Samsung Medical Center

    Head of Strategic Planning Office, Samsung Medical Center

Executive

CEO
Joon Soo Ryu Ph.D, MBA

Ph.D, KAIST; MBA, Dartmouth College

Vice President of Strategic Planning & BD, GC Pharma

Regional Director of Commercial Excellence, Mundipharma

Principal, IMS Consulting Group

CBDO
Jae Hoon Chung Ph.D

M.S., Ph.D, Seoul National University, College of Pharmacy

Chief Operating Officer, SPARK Biopharma

Head of Research Planning, C&C Research Laboratories

Principal Scientist of R&D Division, Korea Drug Development Fund

CFO
Seung Bo Moon CPA

B.S., Business Administration, Korea University

CFO and COO of Hanel

CFO of Meere Company

CPA of Samil PwC

Director of Clinical
Development
Mi Ra Jung Ph.D

B.S., M.S., Ph.D, Ewha Womans University, College of Pharmacy

Director of Pharmacology Division, SPARK Biopharma

Medical Manager of Immuno-oncology, Merck

Senior MSL of Oncology, AstraZeneca

Head of
Research Team
Myun Soo Kim Ph.D

Ph.D & B.S, Korea University

Research Professor of Institute of Convergence Science, Korea University

Research Professor for BK21PLUS Project, Korea University

Senior Researcher, Sookmyung Women’s University

Head of
Strategic Planning Team
Hyun Gun Song Ph.D

Ph.D, Chungnam National University; M.S. & B.S. Kangwon National University

Assistant Professor of Anatomy Class of Medical School, Injae University

Head of Research
Planning Team
Sun Young Park Ph.D

B.S., M.S, & Ph.D, Department of Cell Biology, Sookmyung Women's University

Senior Researcher, Sookmyung Women's University

Senior Researcher, SIS Immunology Research Center, Sookmyung Women's University

Research Professor, Sookmyung Women’s University

2019

  • 03
    Change of corporate name to KINE SCIENCES Co.,Ltd.
    03
    R&D Center of KINE SCIENCES established
    08
    Corporate R&D Center certification acquisition

2018

  • 09
    Transfer of intellectual property rights from Sookmyung Women's University, 2nd time
    10
    Established joint research institute with Korea University
    11
    Dr. Cho, inaugurated as head of the Nanobio Materials Research Center at Korea University
    12
    Certified by Korea Government as a Venture Company

2017

  • 01
    Transfer of intellectual property rights from Sookmyung Women's University, 1st time

2016

  • 08
    Company founded(Bio Pep Co., Ltd.)
    12
    Selected as a new drug development project by the Ministry of New Drug Development Project
Mission
Contributing to better lives of mankind
by developing innovative therapies
Vision 2025
Growing as a unicorn company
carrying out more than five global clinical trials with new molecules

Core Value

  • CHALLENGE
    Pursuing the best through change and innovation
  • FLEXIBILITY
    Being flexible and adaptable to ever-changing environment
  • JUSTNESS
    Sticking to the principle and being honest
  • COMMITMENT
    Being committed to common goal and vision
  • COLLABORATION
    Moving forward hand in hand
Continuous InnovationRaises Hope for Humanity.